Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age above or equal to 18 years at the time of signing informed consent.~* Body mass index (BMI) greater than or equal to 30.0 kg/m\^2~* New York Heart Association (NYHA) Class II-IV~* Left ventricular ejection fraction (LVEF) greater than or equal to 45 percentage at screening~Exclusion Criteria:~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records~* Haemoglobin A1c (HbA1c) greater than or equal to 6.5 percentage (48 mmol/mol) based on latest available value from medical records, no older than 3 months or if unavailable a local measurement at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
- Placebo (semaglutide) (Type: PLACEBO_COMPARATOR): All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).